Valeria RICCIERI

Has grant

Associate Professor

Sapienza University of Rome

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Valeria Riccieri is an Associate Professor at Sapienza University of Rome, Italy. Her research focuses on the safety and efficacy of vaccinations, specifically related to rheumatic autoimmune diseases and systemic sclerosis. Recent publications include studies on the durability of vaccine-induced antibodies, the potential role of interleukin 33 as a biomarker, and the impact of COVID-19 on patients with rheumatic conditions.

Recent Grants

Grant: Close

A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED,ADD-ON TRIAL EVALUATING EFFICACY AND SAFETY OF HYDROXYCHLOROQUINE IN EARLY SYSTEMIC SCLEROSIS (SSc)-HYDROXYSSc

Open Date:

Close Date:

Articles (10)

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Maria Sofia Cattaruzza

Sapienza University of Rome

ITALY

View details

Guido Antonelli

ITALY

View details

Raffaele D’Amelio

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Valeria RICCIERI

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Safety of Multiple Vaccinations and Durability of Vaccine-Induced Antibodies in an Italian Military Cohort 5 Years after Immunization

CAN INTERLEUKIN 33 (IL-33) BE CONSIDERED A VALUABLE BIOMARKER IN THE EARLY STAGES OF SYSTEMIC SCLEROSIS? ANALYSIS OF A MONOCENTRIC COHORT

COVID-19 IN ITALIAN PATIENTS WITH RHEUMATIC AUTOIMMUNE SYSTEMIC DISEASES: RESULTS OF A NATIONWIDE SURVEY STUDY

COVID-19 and systemic sclerosis: analysis of lifestyle changes during the SARS-CoV-2 pandemic in an Italian single-center cohort

COVID-19 and systemic sclerosis: analysis of lifestyle changes during the SARS-CoV-2 pandemic in an Italian single-center cohort

COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study

Complementary effects of carbamylated and citrullinated ll37 in autoimmunity and inflammation in systemic lupus erythematosus

Complementary Effects of Carbamylated and Citrullinated LL37 in Autoimmunity and Inflammation in Systemic Lupus Erythematosus

Covid-19 and rheumatic autoimmune systemic diseases: Role of pre-existing lung involvement and ongoing treatments

EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROPENSITY SCORE CONTROL MATCHED OBSERVATIONAL STUDY OF THE EUSTAR COHORT

Collaborators (3)

Maria Sofia Cattaruzza

Guido Antonelli

Raffaele D’Amelio

Make your next move.